| Literature DB >> 33204694 |
Yanyan Fang1, Jian Liu2, Ling Xin1, Yue Sun2, Lei Wan2, Dan Huang3, Jianting Wen3, Ying Zhang3, Bing Wang4.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that is diagnosed mainly on the basis of patient signs, symptoms, and laboratory indices. However, the exact causes of RA are unclear. Moreover, there is a lack of any method of dynamically evaluating the efficacy of the medication administered to treat RA. Here, we applied a random walk model to reveal the compatibility among the various constituents of traditional Chinese medicine and evaluate their therapeutic efficacy against RA. Drugs commonly used to treat RA were investigated using cluster analysis. The association rule analysis was applied to identify compatibilities among the constituents. A random walk model was developed to evaluate drug efficacy based on an in-house database comprising the clinical records of 9,408 RA patients. Frequently administered medicines were combined into three correlated sets. The evaluation based on the random walk method showed that the drug combination improved ESR, CRP, C3, C4, and IgA more effectively than any single drug. The present study demonstrated that the TCM constituents complement each other and various combinations of them produce different therapeutic effects on RA treatment.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33204694 PMCID: PMC7665920 DOI: 10.1155/2020/4031015
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Schematic diagram of baseline matching algorithm.
Use of Chinese herbal medicine in RA treatment.
| Category | Herb | Number | Property and taste | Meridian tropism |
|---|---|---|---|---|
| Invigorating spleen and resolving dampness |
| 8,248 | Sweet, light, flat | Spleen, kidney |
|
| 7,873 | Pungent, bitter, warm | Spleen, lung | |
|
| 7,644 | Sweet, light, cool | Spleen, stomach | |
|
| 6,926 | Sweet, flat | Spleen, lung, kidney | |
|
| 2,527 | Sweet, flat | Spleen, stomach, liver | |
|
| ||||
| Promoting blood circulation to dredge collaterals |
| 7,813 | Bitter, slightly cold | Heart, liver |
|
| 7,257 | Pungent, warm | Heart, liver | |
|
| 7,034 | Bitter, sweet, flat | Heart, liver | |
|
| 3,992 | Bitter, slightly sweet, warm | Liver, kidney | |
|
| 2,518 | Pungent, warm | Liver | |
|
| ||||
| Wind-dispelling and dehumidification |
| 6,189 | Pungent, salt, warm | Bladder |
|
| 5,247 | Pungent, bitter, cold | Kidney, liver | |
|
| 4,869 | Sweet, cold | Kidney, bladder | |
|
| 2,383 | Sweet, slightly cold | Liver, kidney, lung, small intestine | |
|
| 1,375 | Pungent, bitter, warm | Kidney, bladder | |
|
| ||||
| Heat clearing and detoxification |
| 6,956 | Bitter, sweet, cold | Liver, stomach |
|
| 4,890 | Bitter, sweet, cold | Stomach, larger intestine | |
|
| 2,260 | Bitter, cold | Lung, stomach, larger intestine | |
|
| 1,739 | Bitter, cold | Kidney, bladder | |
|
| 1,583 | Bitter, sweet, cold | Lung, stomach | |
Values indicate the number of times the drug is used. Invigorating spleen and resolving dampness: herbs have efficacy to invigorate the spleen and resolve dampness. Promoting blood circulation to dredge collaterals: herbs have efficacy to promote blood circulation and dredge collaterals. Wind-dispelling and dehumidification: herbs have efficacy to dispel wind and dehumidify. Heat clearing and detoxification: herbs have efficacy to clear heat and detoxify.
Figure 2Cluster analysis of Chinese herbal medicine used in RA treatment. Note: when Euclidean distance = 15, Chinese herbal medicines were divided into three sets. Neither Sigesbeckia orientalis nor Caulis Spatholobi was classified in the other sets.
Correlation of Chinese herbal medicine in RA treatment.
| Items (LHS⇒RHS) | Support | Confidence | Expected confidence | Lift |
|
|---|---|---|---|---|---|
| { | 83.68% | 91.72% | 87.67% | 1.05 | <0.01 |
| { | 83.05% | 91.03% | 87.67% | 1.04 | <0.01 |
| { | 81.25% | 91.03% | 87.67% | 1.04 | <0.01 |
| { | 83.05% | 87.71% | 83.68% | 1.05 | <0.01 |
| { | 87.67% | 87.55% | 83.68% | 1.05 | <0.01 |
| { | 81.25% | 87.55% | 83.68% | 1.05 | <0.01 |
| { | 83.68% | 87.04% | 83.05% | 1.05 | <0.01 |
| { | 81.25% | 86.79% | 83.05% | 1.05 | <0.01 |
| { | 87.67% | 86.23% | 83.05% | 1.04 | <0.01 |
| { | 83.68% | 85.00% | 81.25% | 1.05 | <0.01 |
| { | 83.05% | 84.91% | 81.25% | 1.05 | <0.01 |
| { | 87.67% | 84.36% | 81.25% | 1.04 | <0.01 |
| { | 83.05% | 84.22% | 77.14% | 1.09 | <0.01 |
| { | 83.05% | 82.25% | 74.77% | 1.10 | <0.01 |
| { | 81.25% | 82.14% | 73.94% | 1.11 | <0.01 |
| { | 81.25% | 81.36% | 77.14% | 1.06 | <0.01 |
| { | 83.68% | 81.20% | 77.14% | 1.05 | <0.01 |
Values are % degrees of relevancy.
Figure 3FP-tree of itemset. Note: the number after “:” indicates support of item.
Improvement of immune-inflammatory indices.
| Index | Control group | Experimental group |
| ||
|---|---|---|---|---|---|
|
|
|
|
| ||
| ESR (mm/h) | -24.213 | 0.00 | -27.964 | 0.00 | 0.000 |
| CRP (mg/L) | -31.166 | 0.00 | -33.468 | 0.00 | 0.000 |
| IgA (g/L) | -11.682 | 0.00 | -13.162 | 0.00 | 0.027 |
| IgM (g/L) | -1.004 | 0.32 | -4.466 | 0.00 | 0.017 |
| IgG (g/L) | -13.731 | 0.00 | -16.249 | 0.00 | 0.003 |
| C3 (g/L) | -15.286 | 0.00 | -17.495 | 0.00 | 0.035 |
| C4 (g/L) | -20.878 | 0.00 | -23.099 | 0.00 | 0.000 |
| CCP (mmol/L) | -4.352 | 0.00 | -3.352 | 0.00 | 0.333 |
| RF (U/mL) | -16.528 | 0.00 | -15.815 | 0.00 | 0.432 |
Note: ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IgA: immunoglobulin A; IgM: immunoglobulin M; IgG: immunoglobulin G; C3: complement C3; C4: complement C4; CCP: anticyclic citrullinated peptide; RF: rheumatoid factor. d0 is the difference in the control group before and after treatment. P0 is the comparison between the control group before and after treatment. d1 is the difference in the experimental group before and after treatment. P1 is the comparison between the experimental group before and after treatment. P2 is comparison between both groups after treatment.
Random walking model of immune-inflammatory indices.
| Index | Group | Maximum random fluctuation | Walking positive growth rate | Random fluctuation power law value | Improvement coefficient | Comprehensive evaluation records | Ratio |
|---|---|---|---|---|---|---|---|
| ESR | Control group | 1,078 | 0.171 | 0.398 ± 0.106 | 0.369 | 2,923 | 5.850 |
| Experimental group | 2,899 | 0.238 | 0.483 ± 0.103 | 0.452 | 6,420 | 4.210 | |
| CRP | Control group | 1,515 | 0.225 | 0.427 ± 0.110 | 0.466 | 3,254 | 4.440 |
| Experimental group | 3,490 | 0.275 | 0.412 ± 0.084 | 0.510 | 6,840 | 3.630 | |
| C3 | Control group | 524 | 0.101 | 0.370 ± 0.106 | 0.292 | 1,795 | 9.880 |
| Experimental group | 1,131 | 0.124 | 0.417 ± 0.110 | 0.330 | 3,430 | 8.040 | |
| C4 | Control group | 747 | 0.144 | 0.331 ± 0.113 | 0.416 | 1,795 | 6.930 |
| Experimental group | 1,482 | 0.163 | 0.399 ± 0.111 | 0.432 | 3,430 | 6.140 | |
| IgA | Control group | 362 | 0.007 | 0.359 ± 0.078 | 0.202 | 1,796 | 14.310 |
| Experimental group | 922 | 0.101 | 0.397 ± 0.069 | 0.269 | 3,426 | 9.860 |
Note: ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; C3: complement C3; C4: complement C4; IgA: immunoglobulin A.
Figure 4Random walking model of immune-inflammatory indices in RA patients. Note: green line represents the experimental group. Blue line represents the control group. Length of horizontal line increases with the number of walking steps. Height of vertical line increases with intervention efficacy and response.